MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Biosimilars and Bioanalytical Methods
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

876 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
876 works in the cohort · of 4,299,418page 3 of 18

Labels cover 4 of 876 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 876 of 876 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

aboutno affunlabeled
Biosimilars in Oncology: Latest Trends and Regulatory Status
Deeksha Joshi, Rubiya Khursheed, Saurabh Gupta, Diksha Wadhwa, Thakur Gurjeet Singh, Sumit Sharma +9 more
2022· review· en· Pharmaceutics· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
34
citations
affunlabeled
Scientific considerations for assessing biosimilar products
Shein‐Chung Chow, Jun Wang, László Endrényi, Peter A. Lachenbruch
2012· article· en· Statistics in Medicine· Immunology and Microbiology
machine prediction:candidate · metaresearchconsensus · metaresearch
31
citations
affunlabeled
Biomarker Assay Validation by Mass Spectrometry
Carmen Fernández‐Metzler, Brad Ackermann, Fabio Garofolo, Mark E. Arnold, Binodh DeSilva, Huidong Gu +5 more
2022· article· en· The AAPS Journal· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
26
citations
afffundno abstractunlabeled
The effect of hematocrit on solid-phase microextraction
Nathaly Reyes‐Garcés, Md. Nazmul Alam, Janusz Pawliszyn
2017· article· en· Analytica Chimica Acta· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
24
citations
aboutno affunlabeled
Biosimilars in inflammatory bowel disease
Fernando Gomollón
2015· review· en· Current Opinion in Gastroenterology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
24
citations
affunlabeled
Physicochemical and Biological Characterization of a Biosimilar Trastuzumab
Carlos A. López‐Morales, Mariana P. Miranda‐Hernández, L. Carmina Juárez-Bayardo, Nancy D. Ramírez-Ibáñez, Alexis J. Romero-Díaz, Nelly Piña-Lara +4 more
2015· article· en· BioMed Research International· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
23
citations
affunlabeled
On the interchangeability of biologic drug products
László Endrényi, Chang Chiann, Shein‐Chung Chow, László Tóthfalusi
2012· article· en· Statistics in Medicine· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
22
citations

How this was built: Screen · Findings · About